23:16 , Apr 16, 2019 |  BC Extra  |  Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
19:25 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

The bacterial AgrA inhibitor apcidin for MRSA infection

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus Cell culture and mouse studies suggest the S. aureus AgrA inhibitor apcidin could help treat methicillin-resistant S. aureus (MRSA) infection. In four strains of S. aureus , the natural...
19:25 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting NOX2 or FOXC1 to treat AML and CML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML) Cell culture and mouse studies suggest inhibiting NOX2 or its downstream mediator FOXC1 could help treat AML and CML. In AML cells from...
15:48 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture and mouse studies suggest IL-37 could help treat inflammation. In mouse macrophages treated with lipopolysaccharide (LPS), transgenic expression of human IL-37 decreased inflammatory cytokine levels compared with no transgene expression. In...
02:03 , Feb 23, 2019 |  BioCentury  |  Product Development

Benchmarks for NASH

Benchmarking clinical value in NASH will require more than the topline data reported this week by Intercept Pharmaceuticals Inc. The readout gained Ocaliva obeticholic acid the title of first NASH therapy to meet in Phase...
00:07 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiomyopathy Patient sample studies suggest CRISPR-mediated editing of the B isoform of LAMP2 could help treat Danon disease, a cardiomyopathy caused by a loss-of-function LAMP2 point mutations. In cardiomyocytes from patients, CRISPR-Cas9-mediated correction of...
17:38 , Jan 11, 2019 |  BC Week In Review  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) said on Jan. 7 it reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in...
15:12 , Jan 7, 2019 |  BC Extra  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) has reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in the wake of the...
13:43 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample and mouse studies suggest inhibiting MUC5B polymerization could help treat pulmonary fibrosis. In lung samples from IPF patients, epithelial cell levels of MUC5B, which forms polymeric gels in alveoli, and...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...